TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06134414: A Multi-center, Randomized, Parallel, Open-label Clinical Phase II Study, to Evaluate the Efficacy and Safety of MY008211A in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients With Signs of Active Hemolysis

Sponsor: Wuhan Createrna Science and Technology Co., Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06134414 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06134414 Rescue Dossier →